In the landscape of biopharmaceutical innovation, Ivan Kairatov stands as a prominent figure whose work bridges the gap between high-throughput technology and therapeutic application. With a career rooted in deep-tier research and development, Kairatov has dedicated years to understanding how specific molecular interactions can be harnessed to treat complex inflammatory disorders. His expertise is particularly relevant today as the industry shifts away from broad-spectrum immunosuppressants toward precision medicine that preserves the body’s natural defenses. In this conversation, we explore the emergence of ENDOtollins, a breakthrough class of compounds designed to selectively disrupt the cellular machinery responsible for chronic inflammation without leaving patients vulnerable to external pathogens.
The discussion delves into the limitations of current gold-standard treatments, such as hydroxychloroquine, which often result in debilitating side effects like vision damage and gastrointestinal distress due to their non-specific nature. We examine the innovative methodology of screening tens of thousands of compounds within intact cellular environments, a technique that ensures experimental success translates more effectively into living organisms. Furthermore, the dialogue touches on the potential for these new molecules to address acute medical crises like cytokine storms in respiratory infections or cancer therapies, and how this research provides a vital blueprint for tackling neurodegenerative diseases through the lens of cellular stress.
Traditional autoimmune treatments often cause gastrointestinal distress or vision damage by broadly blocking cellular compartments. How does targeting the specific “molecular handshake” between Munc13-4 and syntaxin 7 avoid these systemic issues, and what specific metrics indicate that the body’s primary antiviral defenses remain functional during this process?
The primary challenge with legacy treatments like hydroxychloroquine is that they act like a blunt instrument, broadly disrupting endosomes—the vital sorting centers inside our cells. When you interfere with these compartments across the entire body, you inevitably run into systemic toxicity, which is why we see so many of the 15 million Americans suffering from autoimmune diseases struggling with vision loss or severe digestive issues. Our approach pivots toward surgical precision by focusing on the interaction between two specific proteins: Munc13-4 and syntaxin 7. This “molecular handshake” is the gatekeeper for inflammatory signaling, and because Munc13-4 is primarily concentrated within immune cells rather than every cell in the body, we can calm the immune system without collateral damage to other organs. During our testing of the lead compound ENDO12, the most critical metric was the observation of a completely normal antiviral immune response when the subjects were exposed to a virus. This confirms that while we are silencing the internal triggers of chronic inflammation, the body’s fundamental ability to recognize and fight external viral threats remains entirely intact and vigilant.
Screening 32,000 compounds within intact cellular environments is a departure from standard protein extraction methods. Why is maintaining this natural environment critical for identifying molecules like ENDO12, and can you walk through the step-by-step advantages this approach provides when transitioning from laboratory models to living organisms?
Standard drug screening often relies on “test-tube” chemistry where proteins are extracted and isolated, but this strips away the complex architecture of the cell that actually dictates how a drug performs. By screening 32,000 compounds within intact cellular environments, we ensured that the candidates were interacting with the Munc13-4–syntaxin 7 complex exactly where it lives—inside the delicate membranes of the endosomes. This method provides a significant advantage because it filters out compounds that might look good in a vacuum but fail to penetrate cell walls or find their targets in a crowded intracellular space. Step-by-step, this “cell-first” approach allows us to identify molecules that are naturally biocompatible from the very beginning of the discovery phase. When we move from these cellular models to living organisms, we see a much higher success rate because the compound has already proven its ability to navigate the complex internal geography of a functioning immune cell. It essentially removes the guesswork that usually plagues early-stage drug development, making the transition to animal models far more predictable and robust.
Toll-like receptors can mistakenly trigger chronic inflammation by detecting a person’s own DNA or RNA. How do ENDOtollins distinguish between these internal triggers and external threats like viruses, and what specific changes in inflammatory markers like IL-6 or IFN-γ have been observed during successful treatment?
In conditions like lupus or rheumatoid arthritis, the immune system’s Toll-like receptors (TLRs) lose their ability to distinguish between “self” and “other,” often reacting violently to a person’s own genetic material released from neutrophil-extracellular traps. ENDOtollins work by specifically dampening this overactive sensing mechanism, effectively raising the threshold required to trigger an inflammatory cascade. When we introduced the compound ENDO12 into models with hyper-active TLRs, we witnessed a dramatic and measurable cooling of the “inflammatory fire.” Specifically, blood levels of key immune activators like IL-6 and IFN-γ dropped significantly, indicating that the systemic alarm bells were being silenced. This is a profound shift because these markers are the primary drivers of the swelling and tissue damage seen in chronic disease. By lowering these levels while maintaining the machinery for viral detection, we provide a pathway to treat the disease at its molecular root rather than just masking the symptoms with general steroids.
Cytokine storms in cases of severe respiratory infections or certain cancer therapies present life-threatening inflammatory challenges. Beyond chronic autoimmune conditions, how could these new compounds be adapted for acute emergency settings, and what role does the inhibition of myeloperoxidase play in stabilizing these patients?
The potential for ENDOtollins to treat acute cytokine storms, such as those seen in severe COVID-19 cases or as a side effect of CAR-T cancer therapies, is one of the most exciting frontiers of this research. These emergency situations are characterized by a runaway loop of IL-6 production that can lead to rapid organ failure and death. Because our compounds target the specific protein interactions that facilitate this massive release of inflammatory signals, they could potentially be used as a “kill switch” for the hyper-immune response in an ICU setting. A critical part of this stabilization is the significant reduction in the enzyme myeloperoxidase, which we observed in our successful trials. Myeloperoxidase is often a marker of oxidative stress and tissue damage; by inhibiting its surge, we can protect vital organs from the corrosive effects of a cytokine storm. This suggests that ENDOtollins aren’t just for long-term management of arthritis, but could be repurposed as life-saving interventions when the immune system begins to tear the body apart in an acute crisis.
Moving from experimental compounds to clinical use requires significant optimization of a molecule’s chemistry. What are the primary hurdles in refining ENDOtollins for human trials, and how might these tools be used to investigate other conditions involving cellular stress, such as neurodegenerative diseases?
The journey from a laboratory success like ENDO12 to a human prescription involves a rigorous process of chemical refinement to ensure the molecule is stable, long-lasting, and easily absorbed by the human body. Our primary hurdle is fine-tuning the chemistry to maintain its high selectivity for the Munc13-4–syntaxin 7 interaction while ensuring it can be delivered in a way that is convenient for patients, such as an oral tablet. Beyond the immediate goal of treating autoimmune disease, these compounds serve as high-precision tools that allow us to peer into the fundamental workings of the cell. Because they interact with endosomes and lysosomes—compartments that are heavily implicated in how the brain handles cellular waste—we can use these molecules to study the pathways of neurodegeneration. If we can understand how these compartments become stressed or dysfunctional in immune cells, we can apply those same mechanistic insights to diseases like Alzheimer’s or Parkinson’s. This research effectively provides us with a new set of molecular keys to unlock mysteries across a vast spectrum of human pathology.
What is your forecast for the future of targeted autoimmune therapies?
I believe we are standing on the precipice of a “post-immunosuppression” era where the goal of therapy is no longer to simply shut down the immune system, but to intelligently modulate it. In the coming decade, I forecast that we will see a move away from broad-spectrum drugs that leave patients vulnerable to infection, replaced by a new generation of “disease-modifying” precision tools like ENDOtollins. We will likely see treatments tailored to the specific molecular handshake driving a patient’s unique pathology, allowing them to live lives free from both the symptoms of their disease and the heavy side effects of their medication. This shift will be driven by our increasing ability to screen drugs within the living architecture of the cell, ensuring that the therapies of tomorrow are as safe as they are effective. Ultimately, the future lies in these precision-targeted approaches that respect the body’s natural defenses while silencing the specific errors that lead to chronic illness.
